Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) recovered 33.33% of its value since hitting low of $1.20. The recent move of -6.98% drop pushed the stock to close at $1.6 when trading ended on Oct. 30, 2017. At recent session, the prices were hovering between $1.57 and $1.77. This company shares are 321.88% off its target price of $6.75 and the current market capitalization stands at $17.3M. The recent change has given its price a 6.71% lead over SMA 50 and -92.88% deficit over its 52-week high. The stock witnessed 11.11% gains, 25.98% gains and -35.48% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found ANTH’s volatility during a week at 12.86% and during a month it has been found around 10.56%.Anthera Pharmaceuticals, Inc. (ANTH) Top Holders
Institutional investors currently hold around $5 million or 28.9% in ANTH stock. Look at its top three institutional owners. Bvf Inc/Il owns $1.73 million in Anthera Pharmaceuticals, Inc., which represents roughly 10.01% of the company’s market cap and approximately 34.62% of the institutional ownership. Similar statistics are true for the second largest owner, Sabby Management, Llc, which owns 592,672 shares of the stock are valued at $1.02 million. The third largest holder is Vanguard Group Inc, which currently holds $587 thousand worth of this stock and that ownership represents nearly 3.39% of its market capitalization.Anthera Pharmaceuticals, Inc. 13F Filings
At the end of 06/30/2017 reporting period, 16 institutional holders increased their position in Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) by some 751,391 shares, 47 decreased positions by 1,369,679 and 4 held positions by 827,785. That puts total institutional holdings at 2,948,855 shares, according to SEC filings. The stock grabbed 6 new institutional investments totaling 160,887 shares while 29 institutional investors sold out their entire positions totaling 791,733 shares.
Multiple company employees have indulged in significant insider trading. Anthera Pharmaceuticals, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that President & CEO Thompson John Craig has acquired 8,550 shares of Anthera Pharmaceuticals, Inc. (ANTH) in trading session dated Sep. 20, 2017. These shares are worth $11,286 and were traded at $1.32 each. The SEC filing shows that Thompson John Craig performed a purchase of 10,400 shares. The President & CEO added these shares by way of transaction on Sep. 07, 2017. The company’s shares were assimilated at $1.43 per share worth to an investment of some $14,872 on account of Thompson John Craig.
Director, Truex Paul F, purchased 5,000 common shares of Anthera Pharmaceuticals, Inc. (ANTH) in the open market. In a transaction dated Sep. 07, 2017, the shares were bought at an average price of $1.34, giving away a sum of $6,700. After this purchase, 16,793 common shares of ANTH are directly owned by the insider, with total stake valued at $26,869.
In the transaction dated Nov. 13, 2015, the great number of shares disposed came courtesy the Chief Medical Officer; Hislop Colin disposed a total of 1,563 shares at an average price of $42.48, amounting to approximately $66,396. The insider now directly owns 2,631 shares worth $4,210.Anthera Pharmaceuticals, Inc. (ANTH) Analyst Guide
Several analysts have released their opinion on Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH), with 1 analysts believing it is a strong buy. Whereas 2 of them predict the stock is a hold. Also, there are 0 buy, 0 sell and 0 strong sell ratings, collectively assigning a 2.33 average brokerage recommendation.